Latest Aprea Therapeutics News & Updates

See the latest news and media coverage for Aprea Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Aprea Therapeutics

Biopharmaceutical company developing targeted cancer therapeutics

aprea.com

Headquarters: Doylestown, United States
Company type: Public company
Number of employees: 2–20
Industry: Pharmaceuticals

Last updated Today

Latest news about Aprea Therapeutics

In short: Aprea Therapeutics reported a stock surge following its Q2 2026 earnings beat and accelerated progress for its APR-1051 cancer trial.

Company announcements

June 1 Aprea Therapeutics

Aprea Therapeutics reports updated phase one WEE1 inhibitor data

Patients show partial responses and stable disease with manageable side effects, while dose expansion aims to finish by the second quarter of 2027.

May 13 Aprea Therapeutics

Aprea Therapeutics reports Q1 2026 financial results and updates

The company raised $30 million via private placement, holds $46.5 million in cash, highlighted early efficacy data for APR-1051, and appointed a new chief medical advisor.

March 30 Aprea Therapeutics

Aprea Therapeutics confirms partial response to its WEE1 inhibitor program

The Phase 1 ACESOT-1051 trial shows sustained tumor reduction in biomarker-defined cancers with manageable side effects and ongoing dose escalation plans.

March 16 Aprea Therapeutics

Aprea Therapeutics reports fourth quarter and full year 2025 results

The company recorded a $2.5 million quarterly net loss, raised approximately $8.7 million through private placements, and highlighted early clinical progress for its WEE1 inhibitor APR-1051.

Media coverage

Yesterday Seeking Alpha

Aprea Therapeutics records second consecutive surge, jumping another 22%

Aprea Therapeutics (APRE) stock surges on earnings beat and APR-1051 Phase 1 cancer trial updates—see key levels, cash runway and what's next.

August 12 Finanzen.ch

Aprea Therapeutics: Balance sheet for the expired quarter

Aprea Therapeutics published the balance sheet for the most recent quarter on 08/12/2026, which ended on 06/30/2026. A loss per...

July 29 Markets Insider

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity...

February 18 Nasdaq

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

DOYLESTOWN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that...

Never miss news about Aprea Therapeutics

Track Aprea Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Aprea Therapeutics competitors & trending companies

Browse news for competitors to Aprea Therapeutics and other trending companies.